MM Regan

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

M. Dowsett, Torsten O. Nielsen, Roger A’Hern et al. · JNCI Journal of the National Cancer Institute · 2011 · 2K citations · Full text

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

Giuseppe Viale, MM Regan, Patrizia Dell’Orto et al. · Annals of Oncology · 2011 · 104 citations · Full text

Which Patients, Epidemiology, Health Policy +12

Abstract S1-8: Outcome According to CYP2D6 Genotype among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial

B Leyland-Jones, MM Regan, Mark Bouzyk et al. · Cancer Research · 2010 · 53 citations

Breast Oncology, Cyp2d6 Genotype, Gynecology +20

Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study

Shrushma Loi, Anita Giobbe-Hurder, Andrea Gombos et al. · Cancer Research · 2018 · 49 citations

Abstract Gs2-06, Breast Oncology, Immunology +18

Central Review of ER, PgR and HER2 in BIG 1-98 Evaluating Letrozole vs. Letrozole Followed by Tamoxifen vs. Tamoxifen Followed by Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.

Giuseppe Viale, MM Regan, Patrizia Dell’Orto et al. · Cancer Research · 2009 · 23 citations

Breast Oncology, Gynecology, Pharmacotherapy +20